Tag Wart Corn R-Emovr Fast Acting Liquid

Description

The product is identified by SPL Code 34089-3 and is presented as a white to off-white, round, biconvex tablet. Each tablet is debossed with "A" on one side and "123" on the opposite side. It contains 500 mg of Acetaminophen as the active ingredient. The formulation includes the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, povidone, talc, hypromellose, titanium dioxide, polyethylene glycol, iron oxide red, and iron oxide yellow.

Uses and Indications

This drug is indicated for the treatment of warts. It is intended for external use only and must not be applied to healthy skin.

For optimal results, the following application directions should be adhered to: the wart should be soaked in warm water for 5 minutes, thoroughly dried, and then one drop of the drug should be applied with the provided applicator to ensure complete coverage of each wart. After application, the drug should be allowed to dry. If desired, self-adhesive cushioning pads may be used to cover the wart.

The application process should be repeated once or twice daily as needed, for a duration of up to 12 weeks, until the wart is removed.

No teratogenic or nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. Warts should be soaked in warm water for 5 minutes, after which they must be dried completely. Using the provided applicator, one drop of the medication should be applied at a time to ensure complete coverage of each wart. Following application, the treated area should be allowed to dry.

If desired, self-adhesive cushioning pads may be used to cover the wart. This treatment may be repeated once or twice daily as needed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Patients with diabetes should not use this product due to potential complications associated with glycemic control.

Individuals with poor circulation are advised against use, as it may exacerbate their condition.

Application is contraindicated on irritated skin or any area that is infected or reddened, as this may lead to further irritation or infection.

The product should not be applied to moles, birthmarks, warts with hair growing out of them, genital warts, or warts located on the face or mucous membranes, due to the risk of adverse reactions.

Inhalation of vapors is contraindicated; if exposure occurs, immediate cessation of use is required.

In the event of contact with the eyes, it is essential to flush with water for 15 minutes and seek medical attention if discomfort persists.

This product should be kept out of the reach of children. If ingested, immediate medical attention or contact with a poison control center is necessary.

Warnings and Precautions

For external use only, this product may cause skin irritation and dryness, particularly if used concurrently with other topical acne medications or immediately following their application.

Healthcare professionals should exercise caution when recommending this product to patients with diabetes or those who exhibit poor circulation, especially on irritated skin or in areas that are infected or reddened. This includes moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes.

In the event that the product comes into contact with the eyes, it is imperative to flush the eyes with water for a minimum of 15 minutes. Inhalation of vapors should be strictly avoided. Should any discomfort persist, patients are advised to discontinue use and seek medical consultation.

Emergency medical assistance should be sought immediately if the product is ingested, or alternatively, contact a Poison Control Center without delay.

Patients should be instructed to stop using the product and consult their healthcare provider if discomfort continues.

Side Effects

Patients using this product should be aware that it is for external use only. The use of this product may lead to skin irritation and dryness, particularly if it is applied concurrently with other topical acne medications or immediately following their use. It is important for patients to monitor their skin condition and discontinue use if significant irritation or dryness occurs.

Drug Interactions

Concurrent use of other topical acne medications may lead to skin irritation and dryness when applied simultaneously or immediately after the application of this product. It is advisable to monitor the skin condition closely and consider spacing the application of these products to minimize adverse effects.

Packaging & NDC

Below are the non-prescription pack sizes of Tag Wart Corn R-Emovr Fast Acting Liquid (skin tag remover salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The product has not been evaluated for safety in pregnant women, and its use is contraindicated during pregnancy due to potential risks to the fetus. There are no established safety guidelines for the use of salicylic acid during pregnancy; therefore, it should be avoided. While no specific dosage modifications for pregnant women are provided, caution is advised. Pregnant women are encouraged to consult a healthcare provider before using this product to discuss potential risks and alternative options.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, it is imperative that immediate medical attention is sought. Healthcare professionals should advise patients or caregivers to contact a poison control center without delay if the substance has been ingested.

Symptoms of overdosage may vary depending on the specific substance involved; therefore, a thorough assessment of the patient's condition is essential. Healthcare providers should monitor for any adverse effects and provide supportive care as necessary.

Management of overdosage typically involves symptomatic treatment and may require specific interventions based on the clinical presentation. It is crucial to follow established protocols for the management of overdose cases, which may include activated charcoal administration if appropriate and within the recommended time frame post-ingestion.

In all cases of suspected overdosage, prompt and effective communication with poison control centers and adherence to local guidelines are recommended to ensure optimal patient outcomes.

Nonclinical Toxicology

No relevant information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no pertinent data concerning nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion. In the event that the product is swallowed, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

Patients should be informed that the product is contraindicated for individuals with diabetes, poor circulation, or those with irritated skin. Additionally, it should not be used on any areas that are infected or reddened, including moles, birthmarks, warts with hair growing out of them, genital warts, or warts located on the face or mucous membranes.

When using the product, patients must be cautioned to avoid contact with the eyes. If the product does come into contact with the eyes, they should flush the eyes with water for at least 15 minutes. It is also important to advise patients not to inhale any vapors associated with the product.

Healthcare providers should encourage patients to discontinue use and consult a doctor if any discomfort persists after application.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure, to ensure optimal stability. Freezing the product is not recommended, as it may compromise its quality. After opening, the product should be discarded to prevent any potential degradation or contamination.

Additional Clinical Information

The product is administered topically and may be applied once or twice daily as needed for a duration of up to 12 weeks. Clinicians should counsel patients to avoid application on areas with diabetes, poor circulation, irritated skin, infections, reddened skin, moles, birthmarks, warts with hair, genital warts, or warts on the face or mucous membranes.

Patients should be advised to flush their eyes with water for 15 minutes if the product comes into contact with them, and to avoid inhaling vapors. If discomfort persists, they should discontinue use and consult a healthcare professional. It is important to keep the product out of reach of children, and in the event of ingestion, medical attention or contact with a poison control center is recommended.

Drug Information (PDF)

This file contains official product information for Tag Wart Corn R-Emovr Fast Acting Liquid, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)